UBS raised its price target for Eli Lilly to $1,425, outpacing other Wall Street banks, but new prescription data and high expectations ahead of earnings add risk for investors holding LLY shares into August
Wall Street's bullishness on Eli Lilly intensified in July, with UBS setting a new price target of $1,425-higher than recent targets from Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan. The move comes as Lilly's diabetes and obesity drugs, Mounjaro and Zepbound, continue to drive rapid revenue growth, but also as new prescription data for its oral GLP-1 pill, Foundayo, raises questions about whether the company can sustain its momentum.
Analyst Targets Surge
On July 13, UBS analyst Michael Yee increased his 12-month price target for Eli Lilly from $1,250 to $1,425, maintaining a buy rating. That target implies roughly 24% upside from the stock's July 14 close of $1,152.54. Other major banks also raised their targets this month: Guggenheim to $1,273, Bank of America to $1,334, Truist to $1,370, and Bernstein to $1,385. The consensus reflects confidence in Lilly's ability to capitalize on surging demand for its GLP-1 drugs, which are used to treat diabetes and obesity.
UBS's call stands out because it coincides with mixed signals from prescription data. While Mounjaro and Zepbound have delivered blockbuster sales, Foundayo's launch has been less convincing. According to IQVIA data cited in a July 10 Jefferies note, Foundayo prescriptions have plateaued at around 19,550 per week, down from a week-10 peak of 21,648. For comparison, Novo Nordisk's oral Wegovy pill surpassed 105,000 weekly prescriptions at the same point after launch. Jefferies projects $71 million in debut-quarter Foundayo sales, well below the Wall Street consensus of $130 million.
Revenue Growth and Risks
Lilly's first-quarter 2026 results showed revenue up 56% year-over-year to $19.8 billion, with full-year guidance raised to $82-$85 billion. Mounjaro generated $8.66 billion in global sales, more than double the prior year's quarter, while U.S. Zepbound sales reached $4.16 billion, up 80%. U.S. revenue climbed 43% to $12.1 billion, driven by a 49% jump in volume. Adjusted earnings per share came in at $8.55, beating the $6.66 consensus, according to CNBC. Notably, volume growth-not price increases-drove these results, as realized prices fell in both the U.S. and international markets.
Despite these numbers, the stock has lagged analyst optimism. LLY shares closed at $1,152.54 on July 14, down nearly 5% over the previous five trading days, though still up 11.6% over six months. The stock set an all-time closing high of $1,235.56 on July 7 before pulling back. With a market capitalization near $1.09 trillion and a price-to-earnings ratio around 41, investors are paying a premium for future growth that has yet to fully materialize.
Prescription Data and New Drug Launches
Foundayo, Lilly's oral GLP-1 therapy, was expected to expand the market by appealing to patients who prefer pills over injections. Yet, its prescription growth has stalled, and coverage by major pharmacy benefit managers arrived later than for competitors. Doctors may also be slower to adopt Foundayo, as it is a new compound with less familiarity than oral semaglutide (Wegovy). Employer coverage for GLP-1 drugs remains a separate challenge, potentially limiting demand growth.
Meanwhile, optimism around Kisunla, Lilly's Alzheimer's treatment, is building. The company presented 16 abstracts at the Alzheimer's Association International Conference in London in mid-July, including long-term extension data and research on blood-based diagnostic tests. While these developments could eventually expand the eligible patient pool, Kisunla is not expected to move the revenue needle in the near term.
What to Watch Ahead of Earnings
Lilly is set to report second-quarter results on August 5, and the outcome could determine whether the $1,425 target is realistic. Key issues for investors include whether Foundayo's reported sales match or miss consensus, whether Mounjaro's international growth continues at its current pace, and whether volume gains can keep offsetting falling realized prices. The stock's high valuation means even a single disappointing quarter could trigger a sharper pullback.
For those considering adding LLY to their portfolio, it's worth noting that six major banks have raised their targets in a short span, and the stock is already trading about 8% below its recent high. As with other high-multiple growth stocks, sizing positions carefully is critical, especially when expectations are elevated and new product launches face early headwinds. For a look at how UBS has responded to similar volatility in other sectors, see this analysis of their call on Bloom Energy after a sharp pullback: UBS's approach to buy-the-dip opportunities in volatile stocks.
As of July 2026, Eli Lilly's market capitalization stands near $1.09 trillion, with a 52-week trading range from $623.78 to $1,249.45. The company's first-quarter 2026 revenue of $19.8 billion marked a 56% increase from the prior year, and adjusted earnings per share of $8.55 exceeded analyst expectations. Despite these gains, the stock's price-to-earnings ratio remains elevated, reflecting high investor expectations for continued growth in its diabetes, obesity, and Alzheimer's drug franchises.
GLP-1 drugs like Mounjaro and Zepbound have transformed the competitive landscape for diabetes and obesity treatments, driving rapid revenue growth for Eli Lilly and its peers. These drugs work by mimicking hormones that regulate blood sugar and appetite, leading to improved glycemic control and weight loss. However, the market's enthusiasm has also led to high valuations and increased scrutiny of prescription trends, insurance coverage, and the sustainability of demand. Investors should pay close attention to quarterly sales figures, coverage decisions by pharmacy benefit managers, and the pace of adoption for new therapies, as these factors can quickly shift sentiment and valuation in this fast-evolving sector.
